Relay Therapeutics Has Risen Nearly Ninefold on Hopes for Its Lead Drug – the Model Still Rates It Sell

Relay Therapeutics has no approved products, lost $286 million over the past four quarters and increased its share count by about a quarter in the first half of 2026. The market nonetheless values the clinical-stage biotech at $3.93 billion, with the share price nearly nine times its two-year low. This Relay Therapeutics stock analysis explains why the excitement around its breast cancer drug zovegalisib and the model’s Sell signal can both be true.

What Is Happening With the Stock Price

Relay closed at $17.95 on Wednesday, October 7, after falling 3.4% on Tuesday and 4.2% on Wednesday. On weekly closes its two-year range runs from $2.00 to $20.00, which puts the stock at the upper end of the range, about 10% below the high. On daily closes the peak was $20.75 in early July 2026, so the shares are about 13.5% below that level. The rally began in the second half of 2025 and continued into 2026, when the FDA granted zovegalisib Breakthrough Therapy Designation and the company raised fresh capital. Since August the stock has traded between roughly $17.50 and $20.75.

Quality: Is This a Financially Sound Business?

On conventional measures, Relay is not yet a self-sustaining business, and the 25/100 Quality score reflects that. Revenue over the past twelve months was about $10 million, none of it from product sales, so margin ratios mean little: the gross margin shows as 0.0%, and the -25,949.7% operating margin reflects a second-quarter operating loss of $90.8 million on $0.35 million of revenue. Return on equity is -36.8% and return on assets -22.9%.

The balance sheet is the strength in this Relay Therapeutics stock analysis. Relay held $910.9 million of cash, cash equivalents and investments at June 30, 2026, debt-to-equity is just 0.03 and the current ratio is 18.27. Management expects that cash to fund operations into 2029. Yahoo’s free cash flow figure of -$119 million understates the burn, though: Relay’s reported operating cash outflow over the last four quarters was about $212 million, and its quarterly net loss widened to $83.7 million in the second quarter from $73.3 million in the first.

Growth: Does This Company Have Real Upside?

Revenue-based growth measures are not meaningful here. Yahoo’s 123.2% compound growth rate, labelled five-year, actually covers 2022 to 2025, when annual revenue rose from $1.4 million to $15.4 million, and its -48.3% revenue growth figure compares second-quarter revenue of $0.35 million with $0.68 million a year earlier. Both swing on the timing of one-off payments. The Growth score of 14/100 reflects that, along with an EV/Revenue multiple of 311.73.

The real growth question is clinical. Zovegalisib, a PI3Kα inhibitor, is in the Phase 3 ReDiscover-2 trial in breast cancer patients previously treated with CDK4/6 inhibitors, and holds Breakthrough Therapy Designation in combination with fulvestrant for PIK3CA-mutated HR+/HER2- advanced breast cancer. Relay has chosen a triplet with atirmociclib for first-line use, with a Phase 3 trial expected to start in early 2027, subject to regulatory feedback. Initial Phase 1/2 data in vascular anomalies showed volumetric responses in 60% of patients at 12 weeks. None of this shows up in the financial statements yet, and late-stage trials can fail.

Opportunity: Is Now a Good Time to Enter?

With negative earnings, the P/E is N/A and EV/EBITDA is -10.47, so the model leans on a price-to-book ratio of 4.41 and a free cash flow yield of -3.0%. The result is an Opportunity score of 16/100. The stock sits at the upper end of its two-year range, and the model’s contrarian component stays neutral for a company with a Quality score this low.

Dilution is the other risk. Relay raised $137.1 million net through at-the-market share sales in the first quarter, another $22.1 million in April and $296.8 million net from a follow-on offering in May, and Yahoo’s share count rose from 173.9 million at the end of 2025 to 218.5 million at the end of June. The runway into 2029 reduces the near-term need for more capital, but a clinical setback could hit a stock that has already priced in a good deal of success.

Relay Therapeutics Stock Analysis: The Bottom Line

Our Relay Therapeutics stock analysis finds a well-funded clinical-stage company whose value depends almost entirely on trial outcomes the financial statements cannot yet show. Quality 25, Growth 14 and Opportunity 16 produce a recommendation score of 18/100, and our model rates the stock a Sell. That rating measures current financial fundamentals; it does not try to value a drug pipeline, which is where the bull case lies, with a Breakthrough-designated drug in Phase 3 and cash into 2029. The bear case is a $3.93 billion valuation on about $10 million of revenue, continuing losses and dilution. Buy / Hold / Sell reflects StreetBriefs’ quantitative scoring model, a starting point for further research, not a personalized recommendation to transact.